Sandra Johnson Source Confirmed

OverviewAI-generated summary

Sandra Johnson's research focuses on infectious disease epidemiology, particularly concerning SARS-CoV-2 and COVID-19 responses. Her work has investigated genomic epidemiology in healthcare workers and informed public health strategies for disease elimination in regions like Victoria, Australia. She has also examined viral infections and their pathogenesis, including a review of their role in glaucoma. Johnson's research extends to patient-reported outcomes in clinical trials, such as the PSOARING 3 trial for plaque psoriasis, and analyses of risk factors for nephrotoxicity in patients with Methicillin-Resistant Staphylococcus aureus (MRSA) bacteraemia, drawing on data from the CAMERA2 trial.

Her publications also address the effectiveness of different therapeutic approaches, including a post hoc analysis of the CAMERA2 trial comparing standard therapy with combination therapy for MRSA bacteremia. Additionally, Johnson has explored the development of alternative methods for viral inactivation in biomanufacturing. Her scholarly contributions are reflected in an h-index of 22, with 69 total publications and 3,938 citations, designating her as a highly cited researcher. She also collaborates with Sandy Johnson at the University of Arkansas – Fort Smith on shared publications.

Metrics

• h-index: 22
• Publications: 69
• Citations: 3,938